Cipla Shares Surge 4% as Citi Forecasts Major Growth Catalysts

Cipla shares witnessed a significant rally on Monday, climbing 4% to reach a high of Rs 1,409 on the BSE. This momentum follows a strategic move by international brokerage firm Citi, which has placed the pharmaceutical major on a "90-day Positive Catalyst Watch."

US Market Triggers and Product Approvals

The primary driver behind Citi's optimism lies in several near-term triggers within the United States market. The brokerage maintained a ‘Buy’ rating with a target price of Rs 1,700, implying a potential upside of 25.55%.

Key expectations include the likely approval of gFlovent from Cipla’s Goa facility, which is expected to bolster US revenue. Additionally, the anticipated launch of gVentolin is viewed as a significant growth driver. Citi also highlighted Cipla's dominant position in the US market, noting that its Nintedanib product has already captured nearly 50% of the market share. After a period of recent weakness, the US business is now poised for a substantial revenue rebound.

Domestic Resilience and Regulatory Milestones

While the US market offers high-growth potential, Cipla’s domestic operations remain a bedrock of stability. The India business, which contributes nearly two-thirds of the company's EBITDA, continues to perform robustly, supported by a recovery in its respiratory portfolio.

Beyond sales, regulatory developments could act as secondary catalysts. Citi pointed out that a re-inspection of Cipla’s Indore plant is expected at any time. A favorable outcome and subsequent USFDA clearance would provide additional tailwinds for the stock. Furthermore, easing geopolitical tensions are expected to stabilize raw material costs, helping to protect margins.

Valuation Edge Over Domestic Peers

Despite a challenging Q4—where consolidated net profit saw a 55% YoY decline to Rs 555 crore—Citi believes Cipla's earnings have likely bottomed out following the decline related to gRevlimid.

From a valuation perspective, Cipla appears attractive compared to its Indian counterparts. The stock currently trades at 25x FY27E earnings. Notably, Citi highlighted that Cipla's India business is valued at 7.8 times FY26 sales, which is more reasonable than Mankind Pharma, which trades at 8.5 times. This provides investors with an efficient way to gain exposure to the Indian pharmaceutical market at a competitive price point.

Key Takeaways

  • Significant Upside Potential: Citi has set a target price of Rs 1,700, representing a 25.55% upside, driven by upcoming US product launches and approvals.
  • Dual Growth Engines: The company is benefiting from a strong recovery in its Indian respiratory portfolio and a potential revenue rebound in its US business.
  • Attractive Relative Valuation: Cipla offers a more reasonable valuation for its domestic business (7.8x FY26 sales) compared to key peers like Mankind.